Immunocompromised Focus AiCuris targets immunocompromised patients with precise anti-infective therapies, presenting a clear opportunity to connect with transplant centers, oncology departments, and infectious disease specialists overseeing high-risk patient cohorts.

Strategic Partnerships Premises include PREVYMIS marketed by MSD, highlighting a channel through established pharma partnerships. Explore co-promotion, distribution collaborations, or pipeline licensing to leverage existing commercial reach.

Pipeline with Pritelivir A pivotal Phase 3 candidate, pritelivir, addresses recurrent and resistant HSV infections, suggesting opportunities to engage with specialists treating complex viral infections and to position as a complement or alternative therapy in immunocompromised populations.

Regulatory Momentum FDA priority review for pritelivir signals potential accelerated access timelines. Target payer discussions and IDNs early to align on coverage, reimbursement scenarios, and post-approval studies.

Clinical Evidence Footprint frequent conference activity and late-breaking trial presentations indicate active engagement with clinical decision-makers. Leverage KOLs and symposiums to create advocacy and clinician education initiatives that drive awareness and adoption.